儿童狼疮性肾炎诱导治疗中霉酚酸的最佳暴露量:一项观察性队列研究
该研究纳入86例接受霉酚酸酯(MMF)诱导治疗的儿童狼疮性肾炎(LN)患者,采用有限采样策略计算霉酚酸(MPA)的AUC。结果显示MPA-AUC是与6个月和12个月肾脏缓解及狼疮活动相关的独立因素,维持低活动状态的阈值为30.96和31.19 μg·h·mL⁻¹,减少不良反应的阈值为50.80 μg·h·mL⁻¹,作者建议MPA暴露范围为31.19–50.80 μg·h·mL⁻¹。
要点
- MPA-AUC是儿童LN患者MMF诱导治疗后6个月和12个月肾脏缓解及狼疮活动的独立相关因素。
- 6个月和12个月维持LN低活动状态的MPA-AUC阈值分别为30.96和31.19 μg·h·mL⁻¹。
- 减少MMF相关不良反应的MPA-AUC阈值为50.80 μg·h·mL⁻¹,作者建议MPA暴露范围为31.19–50.80 μg·h·mL⁻¹。
核心结论
- 儿童LN患者MMF的初始和长期治疗应根据MPA-AUC个体化,作者建议MPA暴露范围为31.19–50.80 μg·h·mL⁻¹。
研究设计与样本
- 这是一项基于人群的观察性队列研究,共纳入86例接受霉酚酸酯(MMF)诱导治疗的儿童狼疮性肾炎(LN)患者,采用有限采样策略计算MPA浓度-时间曲线下面积(AUC),并用受试者工作特征分析评估MPA-AUC阈值。
主要发现
- MPA-AUC被确定为与MMF治疗后6个月和12个月肾脏缓解及狼疮活动相关的独立因素,较高的MPA-AUC与肾脏缓解率改善相关,6个月和12个月的阈值分别为29.81和30.63 μg·h·mL⁻¹。
- 维持LN低活动状态的MPA-AUC阈值在6个月和12个月分别为30.96和31.19 μg·h·mL⁻¹。
- 达到MPA-AUC目标阈值的患者更早实现肾脏应答或疾病稳定。
- 减少MMF相关不良反应的MPA-AUC阈值为50.80 μg·h·mL⁻¹。
关键数值与推荐
- 6个月肾脏缓解的MPA-AUC阈值为29.81 μg·h·mL⁻¹,12个月为30.63 μg·h·mL⁻¹。
- 6个月维持LN低活动状态的MPA-AUC阈值为30.96 μg·h·mL⁻¹,12个月为31.19 μg·h·mL⁻¹。
- 减少MMF相关不良反应的MPA-AUC阈值为50.80 μg·h·mL⁻¹。
- 作者建议的MPA暴露范围为31.19–50.80 μg·h·mL⁻¹。
临床怎么用
- 作者认为儿童LN患者MMF的初始和长期治疗应根据MPA-AUC进行个体化。
- 作者建议的MPA暴露范围为31.19–50.80 μg·h·mL⁻¹。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Mycophenolic acid (MPA) is recommended for lupus nephritis (LN) treatment, but with large inter-individual variability in pharmacokinetics (PK). The aim of this study is to reveal the relationship between MPA exposure and disease response and adverse drug reactions in pediatric LN patients. METHOD: This was a population-based observational cohort study. A total of 86 pediatric LN patients treated with mycophenolate mofetil (MMF) for induction therapy were enrolled. The area-under the concentration-time curve (AUC) was calculated using MPA concentrations according to a limited sampling strategy. Receiver operating characteristic analysis was performed to assess the MPA-AUC threshold values. The cumulative incidence of renal remission and inactive systemic lupus erythematosus (SLE) over time was evaluated by Kaplan-Meier's analysis. RESULTS: MPA-AUC was identified as an independent factor associated with renal remission and lupus activity at 6 and 12 months after MMF treatment, and the improved renal remission rates were correlated with higher MPA-AUC, with thresholds of 29.81 and 30.63 μg·h·mL-1 at 6 months and 12 months, respectively. Furthermore, the thresholds for maintaining the hypoactive state of LN were 30.96 and 31.19 μg·h·mL-1at 6 months and 12 months, respectively. Patients reaching target thresholds for MPA-AUC achieved renal response or stable disease earlier. In addition, the MPA-AUC threshold for decreasing MMF-related adverse reactions was 50.80 μg·h·mL-1. CONCLUSION: The initial and long-term treatments of pediatric LN patients with MMF should be individualized according to the MPA-AUC, and the recommended MPA exposure is 31.19-50.80 μg·h·mL-1.
引用
- Zhang L, Chen L, Liu X, et al. Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study. Rheumatology (Oxford). 2024. PMID: 38730553. doi:10.1093/rheumatology/keae264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。